ARTICLE | Emerging Company Profile
Primmune: tolerable TLR7 agonists for systemic immune responses
Emerging Company Profile: San Diego-based Primmune is developing oral host-directed antivirals that activate TLR7 signaling
February 19, 2021 11:21 PM UTC
Primmune is designing oral TLR7 agonists that induce antiviral responses without systemically inducing pro-inflammatory genes.
Primmune Therapeutics Inc. President, Chairman and CEO Charles McDermott told BioCentury, “The TLR7 receptor is your body’s most upstream receptor for identifying novel RNA viruses, and it turns on your immune response,” making the pathogen sensor an attractive target for antiviral and immuno-oncology therapies...